Clinical trials
Phase 2 Hemolysis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Withdrawn | 4 |
| Terminated | 3 |
| Unknown status | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Massachusetts General Hospital | 2 |
| Novartis Pharmaceuticals | 2 |
| Alexion Pharmaceuticals, Inc. | 1 |
| Alnylam Pharmaceuticals | 1 |
| Apellis Pharmaceuticals, Inc. | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Emory University | 1 |
| Forma Therapeutics, Inc. | 1 |
| Helse Fonna | 1 |
| Imperial College London | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hemolysis | 19 |
| Anemia | 7 |
| Anemia, Hemolytic, Autoimmune | 5 |
| Hematologic Diseases | 5 |
| Hemoglobinuria, Paroxysmal | 4 |
| Anemia, Sickle Cell | 3 |
| Anemia, Hemolytic | 2 |
| Genetic Diseases, Inborn | 2 |
| Thrombocytopenia | 2 |
| Atypical Hemolytic Uremic Syndrome | 1 |
Trials
Showing 51 to 19 of 19. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.